In this study, we developed a novel therapeutic candidate, MRS7216, a conjugate of alendronate, one the most commonly used anti-osteoporosis treatments [33], and CGS21680, a specific A2A adenosine receptor agonist that has been previously described to have beneficial effect in bone [14, 34–37]. The gene discussed is ADORA2A; the disease is osteoporosis.